Aphaia Pharma has launched a phase 2 trial to evaluate its lead candidate APH-012 for prediabetes. The Zug-based company has announced that the first patient has been dosed with this drug formulation. A phase 1 trial has already demonstrated the drug candidate's ability to safely restore the body’s own release of hormones in individuals with obesity. The phase 2 trial will now look at its safety and efficacy in both individuals with obesity and those with prediabetes.
Prediabetes is becoming increasingly prevalent worldwide, according to Dr Christian Sina, the Principal Investigator for the Aphaia Phase 2 trial program, and it progresses to manifest type 2 diabetes in a large proportion of patients. “I look forward to evaluating APH-012’s unique mechanism of action and its potential to provide a much-needed solution to slow down or even revert prediabetic conditions.”
“We are pleased to continue to evaluate APH-012 in additional indications beyond obesity in the clinic,” said Kai Deusch, Chief Business & Medical Officer. “We believe in the potential of our unique approach to help treat multiple metabolic diseases.”
Aphaia Pharma is based in Zug and has a global team of experts in Switzerland, the U.S. and Canada. The company has partnered its clinical and commercial supply development and manufacturing with a GMP-certified partner in Puerto Rico. ce/mm
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space